Gilead Sciences | GILD - Debt

Stock Price
152.43
Daily Change
3.06 2.05%
Monthly
22.58%
Yearly
58.72%
Q1 Forecast
137.58

Gilead Sciences reported $24.95B in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
ALKERMES USD 72.68M 293.32M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.95B 6M Jun/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
J&J USD 45.8B 4.97B Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025